Tegafur-FT-207-NSC-148958-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemETegafurCat. No.: HY-17400CAS No.: 17902-23-7Synonyms: FT 207；NSC 148958分式: CHFNO分量: 200.17作靶點(diǎn): Nucleoside Antimetabolite/Analog作通路: Cell Cycle/DNA Damage儲存式: 4C, protect from light* In solvent : -80C, 6 months; -20C, 1 month (pr

2、otect fromlight)溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 48 mg/mL (239.80 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 4.9958 mL 24.9788 mL 49.9575 mL5 mM 0.9992 mL 4.9958 mL 9.9915 mL10 mM 0.4996 mL 2.4979 mL 4.9958 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL A

3、CTIVITY物活性 Tegafur (FT 207; NSC 148958)是抗癌劑5-FU的前藥。IC50 & Target Nucleoside antimetabolite/analog體外研究Tegafur is bioactivated to 5-FU by liver microsomal cytochrome P450 enzymes. 5-FU is subsequentlyconverted into its active metabolites 5-fluoro-deoxyuridine-monophosphate (FdUMP) and 5-fluorouridine-

4、1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEtriphosphate (FUTP) intracellularly; these metabolites inhibit the enzyme thymidylate synthase andintercalate into RNA, resulting in decreased thymidine synthesis, reduced DNA synthesis, disrupted RNAfunction, and tumor cell cytotoxicity.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) J

5、 Mol Med (Berl). 2019 Jun 14.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Sotaro Sadahiro, Toshiyuki Suzuki, Akira Tanaka, et al. Association of right-sided tumors with high thymidine phosphorylase geneexpression levels and the response to oral uracil and tegafur/leucovorin

6、chemotherapy among patients with colorectal cancer. CancerChemotherapy and Pharmacology. 2012, 70 (2): 285-291.2. Jos L. Ariasa, et al. Engineering of an antitumor (core/shell) magnetic nanoformulation based on the chemotherapy agent ftorafur.Colloids and Surfaces A: Physicochemical and Engineering

7、Aspects. 2011,384(1-3): 157-163.3. Gabriel N. Hortobagyi, William Heim, Laura Hutchins, et al. A phase 2 study of a fixed combination of uracil and ftorafur (UFT) andleucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer. 2010, 116(6): 14

8、40-1445.4. K. Fujita, H. Nakayama, W. Ichikawa, et al. Pharmacokinetics of 5-Fluorouracil in Elderly Japanese Patients with Cancer Treated with S-1 (a Combination of Tegafur and Dihydropyrimidine Dehydrogenase Inhibitor 5-Chloro-2,4-dihydroxypyridine). Drug Metab Dispos. 2009Jul;37(7):1375-7. doi: 10.1124/dmd.109.027052. Epub 2009 Apr 23.5. Tegafur-uracilMcePdfHeightCaution: Product has not been fully validated for medical applicati